These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 234295)

  • 21. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.
    de Gast GC; The TH; Schraffordt Koops H; Huiges HA; Oldhoff J; Nieweg HO
    Cancer; 1975 Oct; 36(4):1289-97. PubMed ID: 1175127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of disseminated malignant melanoma with high-dose oral BCG.
    Varella AD; Bandiera DC; de Amorim AR; Calvis LA; Santos IO; Escaleira N; Gentil F
    Cancer; 1981 Sep; 48(6):1353-62. PubMed ID: 7023654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
    Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E
    Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy].
    Lejeune FJ; Bernheim JL; Vanwijck R
    Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
    Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
    J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
    [No Abstract]   [Full Text] [Related]  

  • 32. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M; Schenk M; Lee DJ
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
    Bulkley GB; Cohen MH; Banks PM; Char DH; Ketcham AS
    Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
    Golub SH; Forsythe AB; Morton DL
    Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
    Roth JA; Golub SH; Holmes EC; Morton DL
    Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.